U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C10H15N3.H2O4S
Molecular Weight 452.571
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETHANIDINE SULFATE

SMILES

OS(O)(=O)=O.CNC(NC)=NCC1=CC=CC=C1.CNC(NC)=NCC2=CC=CC=C2

InChI

InChIKey=YTIJUXVIZLYQTB-UHFFFAOYSA-N
InChI=1S/2C10H15N3.H2O4S/c2*1-11-10(12-2)13-8-9-6-4-3-5-7-9;1-5(2,3)4/h2*3-7H,8H2,1-2H3,(H2,11,12,13);(H2,1,2,3,4)

HIDE SMILES / InChI
Bethanidine is a post-ganglionic adrenergic neurone-blocking agent which exerts a marked postural hypotensive effect. The precise mechanism whereby bethanidine causes blockade of adrenergic neurones is unknown. An initial sympathomimetic effect has been demonstrated in man and animals, possibly due to release of catecholamines.

CNS Activity

Curator's Comment: Whole body autoradiograms showed a high concentration of drug in rat tissues rich in adrenergic nerve terminals, but insignificant penetration, if any, of the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TENATHAN

Approved Use

Bethanidine (Sulphate) is used in hypertension to reduce the blood pressure.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.4 μg/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETHANIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.5 μg × h/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETHANIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETHANIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETHANIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg/kg, 1 times / day
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Side effects of hypotensive agents evaluated by a self-administered questionnaire.
1973 Sep 1
Do antihypertensive drugs really cause depression?
1974 Sep
Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure.
1975 Oct
Dihydroergotamine: an effective treatment for postural hypotension due to antihypertensive drugs (ganglion-blocking agents excepted).
1976
Exertional hypotension due to postganglionic sympathetic blocking drugs.
1976 Aug
Patterns of blood-pressure during chronic administration of postganglionic sympathetic blocking drugs for hypertension.
1976 Nov 13
Antiarrhythmic action of bethanidine.
1984 Aug 1
Antiarrhythmic and electrophysiologic actions of bethanidine sulfate in primary ventricular fibrillation or life-threatening ventricular tachycardia.
1984 May 1
Acute electrophysiologic effects of bethanidine sulfate in patients with ventricular tachycardia or fibrillation.
1984 Nov
The aggressive treatment of hypertension.
2003 May 3
eCAM benefits from diversity that derives from CAM.
2005 Sep
Treatment outcome in patients receiving assertive community treatment.
2010 Aug

Sample Use Guides

Initial therapy 0.228 mg/kg 8 hourly Maintenance therapy 0.114 to 0.228 mg/kg 8 hourly
Route of Administration: Oral
In Vitro Use Guide
The effects of bethanidine sulphate, a pharmacological analog of the cardiac antibrillatory drug, bretylium tosylate, were studied on action potentials (APs) and K+, Na+, and Ca2+ currents of single cultured embryonic chick heart cells using the whole-cell current clamp and voltage clamp technique. Extracellular application of bethanidine (0.3 mM) increased the overshoot and the duration of the APs and greatly decreased the outward K+ current (IK) and potentiated the inward fast Na+ currents (INa) and the inward slow calcium current (ICa). However, intracellular introduction of bethanidine (0.1 mM) blocked INa.
Name Type Language
BETHANIDINE SULFATE
JAN   MI   ORANGE BOOK   USAN  
USAN  
Official Name English
GUANIDINE, N,N'-DIMETHYL-N''-(PHENYLMETHYL)-, SULPHATE (2:1)
Systematic Name English
BETHANIDINE SULPHATE
Common Name English
BETANIDINE SULFATE
MART.   WHO-DD  
Common Name English
BETANIDINE SULFATE [JAN]
Common Name English
GUANIDINE, N,N'-DIMETHYL-N''-(PHENYLMETHYL)-, SULFATE (2:1)
Systematic Name English
Betanidine sulfate [WHO-DD]
Common Name English
1-Benzyl-2,3-dimethylguanidine sulfate (2:1)
Systematic Name English
BW-467-C-60
Code English
TENATHAN
Brand Name English
BETANIDINE SULPHATE
Common Name English
BETHANIDINE SULFATE [USAN]
Common Name English
NSC-106563
Code English
BETHANIDINE SULFATE [ORANGE BOOK]
Common Name English
BETANIDINE SULFATE [MART.]
Common Name English
BETHANIDINE SULFATE [MI]
Common Name English
1-BENZYL-2,3-DIMETHYLGUANIDINE SULPHATE (2:1)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C72900
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
NCI_THESAURUS C270
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
FDA ORPHAN DRUG 26087
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
FDA ORPHAN DRUG 32588
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL1201260
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
CAS
114-85-2
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
NSC
106563
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
PUBCHEM
8248
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
FDA UNII
J4THI5N7O2
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
SMS_ID
100000085023
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
RXCUI
81966
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT000194
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
MERCK INDEX
m2458
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY Merck Index
EVMPD
SUB00787MIG
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
CHEBI
31279
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-056-9
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID7048748
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY
NCI_THESAURUS
C65260
Created by admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
PRIMARY